TB Archives – Page 4 of 49 – Treatment Action Group

Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results

December 21, 2023
Dorrit Walsh

This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.

Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030

December 5, 2023
Dorrit Walsh

A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.

Report cover - graphic representation of a target and the text reads: Tuberculosis Research Funding Trends, 2005-2022

2023 Report on TB Research Funding Trends

December 5, 2023
Dorrit Walsh

Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.

Submission on the Right to Access and Take Part in Scientific Progress

November 16, 2023
Dorrit Walsh

TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.

An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis

November 9, 2023
Dorrit Walsh

In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the new DR-TB treatment regimens, including an overview of findings from…

ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS

November 7, 2023
Dorrit Walsh

Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.

Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives

November 6, 2023
Dorrit Walsh

Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.

TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report

October 6, 2023
Dorrit Walsh

TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

October 2023 TAGline cover: Lost in Translation. Features graphic of "TAG Translate" and shows 4 sets of terms: Shorter Treatments = Error: Insufficient Funding; Community Engagement = Error: political hostility; effective prevention = error inadequate awareness; broad screening = error: outdated guidelines

TAGline October 2023

October 4, 2023
Dorrit Walsh

We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.

TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline

October 2, 2023
Dorrit Walsh

TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.